LRP5 and colorectal carcinoma: To explore whether the activation of LRP5 could affect the resistance of CRC cells to chemotherapeutic agents, we treated LRP5‐ACT or NC‐ACT HCT‐116 cells with cisplatin and evaluated the cellular viability by RTCA system and calculated the inhibitory rate of cisplatin on cells.